Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
3.94B
Market cap3.94B
Price-Earnings ratio
42.85
Price-Earnings ratio42.85
Dividend yield
Dividend yield
Average volume
4.50M
Average volume4.50M
High today
$37.70
High today$37.70
Low today
$36.20
Low today$36.20
Open price
$36.94
Open price$36.94
Volume
1.61M
Volume1.61M
52 Week high
$117.33
52 Week high$117.33
52 Week low
$32.99
52 Week low$32.99

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $37.39, giving the company a market capitalization of 3.94B. It carries a P/E multiple of 42.85.

During the trading session on 2026-01-11, Corcept Therapeutics(CORT) shares reached a daily high of $37.70 and a low of $36.20. At a current price of $37.39, the stock is +3.3% higher than the low and still -0.8% under the high.

Trading volume for Corcept Therapeutics(CORT) stock has reached 1.61M, versus its average volume of 4.5M.

The stock's 52-week range extends from a low of $32.99 to a high of $117.33.

The stock's 52-week range extends from a low of $32.99 to a high of $117.33.

CORT News

TipRanks 4d
Corcept Therapeutics put volume heavy and directionally bearish

Bearish flow noted in Corcept Therapeutics (CORT) with 1,232 puts trading, or 1.1x expected. Most active are Feb-26 30 puts and Feb-26 35 puts, with total volum...

Simply Wall St 5d
Corcept Therapeutics Is Down 49.1% After FDA CRL On Relacorilant Effectiveness – Has The Bull Case Changed?

In late 2025, Corcept Therapeutics announced that the FDA issued a Complete Response Letter for its relacorilant NDA in hypertension secondary to hypercortisoli...

Corcept Therapeutics Is Down 49.1% After FDA CRL On Relacorilant Effectiveness – Has The Bull Case Changed?

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.